Successful treatment of early molecular relapse of variant form of secondary acute promyelocytic leukemia with arsenic trioxide

Česká verze

Authors: T. Szotkowski; J. Hubáček; K. Indrák
Authors place of work: Hemato-onkologická klinika FN a LF UP Olomouc
Published in the journal: Transfuze Hematol. dnes,15, 2009, No. 3, p. 148-150.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

We describe the case of young woman with variant form of acute promyelocytic leukemia, who achieved complete molecular remission after the primotherapy according to GIMEMA/EORTC 06952 protocol. Molecular relapse was revealed early (3 months) after maintenance therapy initiation. The induction treatment with arsenic trioxide was administered, followed by two cycles of consolidation treatment combining arsenic trioxide and all-trans retinoic acid. The patient achieved the second molecular remission of leukemia and allogeneic transplantation of hematopoietic stem cells was performed subsequently.

Key words:
acute promyelocytic leukemia, variant form, molecular relapse, arsenic trioxide

Zdroje

1. Amadori S, Buechner T, Burnett A, Cimino G, Doehner H, Fenaux P, Lengfelder E, Lo-Coco F, Lowenberg B, Sanz M. European recommendation for salvage therapy of relapsed acute promyelocytic leukemia (APL) including arsenic trioxide (ATO). 12.12.2007 http://www.scribd.com/doc/5442262/European-recommendation-for-salvage-therapy-of-relapsed-acute-promyelocytic-leukemia-APL-including-arsenic-trioxide-ATO.

2. Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Prac Res Clin Haematol 2008; 21 (4): 659–666.

3. Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience. Cancer 2003; 97(9): 2218–24.

4. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003 Jun 15; 21(12): 2326–34.

5. Tallman MS. Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol 2007; 20 : 57–65.

6. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H, Burnett AK, Lo-Coco F. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113 (9): 1875–1891.

7. Beaumont M, Sanz M, Carli PM. Therapy-Related Acute Promyelocytic Leukemia. J Clin Oncol 2003; 21 : 2123–2137.